Prevalence of low LDL-cholesterol levels and elevated high-sensitivity C-reactive protein levels in apparently healthy Korean adults

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 22, Issue 12, 2012, Pages 1061-1066

  Sung, K C ^a   Rhee, E J ^a   Kim, H ^b   Park, J B ^c   Kim, Y K ^d   Rosenson, R S ^e  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Catholic Kwandong University   (South Korea)

^d Dongguk University Ilsan Hospital   (South Korea)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Apolipoprotein B; C reactive protein; Cardiovascular risk factors; High density lipoprotein cholesterol; Low density lipoprotein cholesterol

Indexed keywords

C REACTIVE PROTEIN; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYRIMIDINE DERIVATIVE; ROSUVASTATIN; SULFONAMIDE;

ARTICLE; ASIAN; BLOOD; BLOOD PRESSURE; COHORT ANALYSIS; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; QUESTIONNAIRE; SOUTH KOREA;

ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; COHORT STUDIES; DYSLIPIDEMIAS; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PYRIMIDINES; QUESTIONNAIRES; REPUBLIC OF KOREA; SULFONAMIDES;

EID: 84870413130     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2011.03.006     Document Type: Article

References (25)

1. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557-1565.
2. Laaksonen D.E., Niskanen L., Nyyssönen K., Punnonen K., Tuomainen T.P., Salonen J.T. C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort. Eur Heart J 2005, 26:1783-1789.
3. Ridker P.M., Rifai N., Cook N.R., Bradwin G., Buring J.E. Non-HDL cholesterol, apolipoproteins A-I and B100, and CRP as risk factors for cardiovascular disease in women. JAMA 2005, 294:326-333.
4. Cushman M., Arnold A.M., Psaty B.M., Manolio T.A., Kuller L.H., Burke G.L., et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women. The Cardiovascular Health Study. Circulation 2005, 112:25-31.
5. Mora S., Rifai N., Buring J.E., Ridker P.M. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. Circulation 2006, 114:381-387.
6. Danesh J., Wheeler J.G., Hirschfield G.M., Eda S., Eiriksdottir G., Rumley A., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387-1397.
7. Pradhan A.D., Manson J.E., Rossouw J.E., Siscovick D.S., Mouton C.P., Rifai N., et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative Observational Study. JAMA 2002, 288:980-987.
8. Wilson P.W., Nam B.H., Pencina M., D'Agostino R.B., Benjamin E.J., O'Donnell C.J. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 2005, 165:2473-2478.
9. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
10. Spatz E.S., Canavan M.E., Desai M.M. From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcomes 2009, 2:41-48.
11. Michos E.D., Blumenthal R.S. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S. J Am Coll Cardiol 2009, 53:931-935.
12. Yang E.Y., Nambi V., Tang Z., Virani S.S., Boerwinkle E., Hoogeveen R.C., et al. Clinical implications of JUPITER (Justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin) in a U.S. population. Insights from the ARIC (Atherosclerosis Risk in Communities) Study. J Am Coll Cardiol 2009, 54:2388-2395.
13. Cushman M., McClure L.A., Lakoski S.G., Jenny N.S. Eligibility for statin therapy by the JUPITER trial criteria and subsequent mortality. Am J Cardiol 2010, 105:77-81.
14. Sung K.C., Ryan M.C., Kim B.S., Cho Y.K., Kim B.I., Reaven G.M. Relationships between estimates of adiposity, insulin resistance, and nonalcoholic fatty liver disease in a large group of nondiabetic Korean adults. Diabetes Care 2007, 30:2113-2118.
15. Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., et al. Harmonizing the metabolic syndrome. A joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
16. Arima H., Kubo M., Yonemoto K., Doi Y., Ninomiya T., Tanizaki Y., et al. High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study. Arterioscler Thromb Vasc Biol 2008, 28:1385-1391.
17. Kelley-Hedgepeth A., Lloyd-Jones D.M., Colvin A., Matthews K.A., Johnston J., Sowers M.R., et al. SWAN Investigators. Ethnic differences in C-reactive protein concentrations. Clin Chem 2008, 54:1027-1037.
18. Cheung B.M., Li M., Ong K.L., Wat N.M., Tam S., Pang R.W., et al. High density lipoprotein-cholesterol levels increase with age in American women but not in Hong Kong Chinese women. Clin Endocrinol (Oxf) 2009, 70:561-568.
19. McQueen M.J., Hawken S., Wang X., Ounpuu S., Sniderman A., Probstfield J., et al. INTERHEART study investigators. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008, 372:224-233.
20. Gordon D.J., Rifkind B.M. High-density lipoprotein - the clinical implications of recent studies. N Engl J Med 1989, 321:1311-1316.
21. Assmann G., Gotto A.M. HDL cholesterol and protective factors in atherosclerosis. Circulation 2004, 109(23 Suppl. 1):III8-III14.
22. Castelli W.P., Garrison R.J., Wilson P.W., Abbott R.D., Kalousdian S., Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986, 256:2835-2838.
23. Shah P.K., Kaul S., Nilsson J., Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 2001, 104:2376-2383.
24. Suk Danik J., Rifai N., Buring J.E., Ridker P.M. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA 2006, 296:1363-1370.
25. Razzouk L., Muntner P., Bansilal S., Kini A.S., Aneja A., Mozes J., et al. C-reactive protein predicts long-term mortality independently of low-density lipoprotein cholesterol in patients undergoing percutaneous coronary intervention. Am Heart J 2009, 158:277-283.